Skip to main content

Table 2 Univariate analysis of transplant outcomes according to donor type

From: Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Outcomea

MSD

MUD

Haplo

p

Acute GvHD, % (95% CI)

    

 Grade II–IV

34 (23–45)

41 (30–51)

32 (27–38)

0.4

 Grade III–IV

15 (8–24)

15 (9–24)

13 (9–17)

0.8

Chronic GvHD, % (95% CI)

    

 Overall

42 (29–54)

50 (37–61)

35 (29–41)

0.01

 Extensive

21 (12–33)

17 (9–27)

11 (7–15)

0.2

NRM, % (95% CI)

21 (12–32)

18 (10–27)

21 (17–26)

0.8

RI, % (95% CI)

28 (17–41)

20 (12–30)

20 (16–26)

0.8

LFS, % (95% CI)

51 (37–63)

62 (50–72)

59 (52–64)

0.8

OS, % (95% CI)

62 (48–73)

69 (57–79)

66 (60–72)

0.8

GRFS, % (95% CI)

35 (23–47)

44 (32–55)

46 (40–52)

0.9

  1. GvHD, graft-versus-host disease; CI, confidence interval; p, p value; NRM, non-relapse mortality; RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; GRFS, graft-versus-host disease-free, relapse-free survival; MSD, matched sibling donor; MUD, matched unrelated donor; Haplo, haploidentical donor
  2. aAcute GvHD: 100-day cumulative incidence; cGvHD, NRM and RI: cumulative incidence at 2 years; DFS, OS and GRFS: survival probability at 2 years